Table 1.
Clinical characteristics of the study group.
| Variables | Total population(n = 22) | CVE group(n = 6) | NO-CVE group(n = 16) |
|---|---|---|---|
| Females, n (%) | 11 (50) | 3 (50) | 8 (50) |
| Age, months | 61 (83) [12; 153] |
26 (32) [14; 83] |
76 (99) [12; 153] |
| BSA, mq | 0.8 (0.5) [0.4; 1.8] |
0.5 (0.3) [0.4; 0.9] |
0.9 (0.6) [0.4; 1.8] |
| Medulloblastoma | 19 (86) | 6 (100) | 13 (81) |
| PNET | 3 (14) | 0 (0) | 3 (20) |
| Metastatic | 15 (68) | 4 (67) | 11 (69) |
| Infant (<3 y.o.) | 9 (40) | 4 (67) | 5 (31) |
| Stem cell transplantation, n (%) | 18 (82) | 5 (83) | 13 (81) |
| HART | 16 (73) | 2 (33) | 14 (88) |
| Radiation dose, Gy | 60 (89) [0; 130] |
0 (45) [0; 88] |
77 (45) [0; 130] |
| Follow-up, months | 51 (89) [7; 140] |
38 (45) [12; 86] |
75 (102) [7; 140] |
| Remission/Off therapy, n (%) | 13 (59) | 2 (33) | 11 (69) |
| Non-CVE-related deaths, n (%) | 7 (32) | 2 (33) | 5 (31) |
| CVE-related deaths, n (%) | 2 (9) | 2 (33) | 0 (0) |
Data are expressed as median (interquartile range) [minimum; maximum values] or absolute number (percentage) as appropriate.
List of abbreviations: BSA, body surface area; CVE, cardiovascular events; HART, hyperfractionated accelerated radiotherapy; PNET, primitive neuroectodermal tumors; y.o., years old.